Approval · Notice of Compliance 161 · 2004
VIAGRA: Notice of Compliance 161
Issued March 8, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 161
- Date
- March 8, 2004
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph revisions regarding safety of sildenafil in subjects with treated hypertension, coronary artery disease and stable angina
- Therapeutic class
- Cgmp-specific phosphodiesterase type 5 inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIAGRA | Not yet assigned | — |
Medicinal ingredients
- SILDENAFIL CITRATE 25 MG per TAB
- SILDENAFIL CITRATE 50 MG per TAB
- SILDENAFIL CITRATE 100 MG per TAB